Transplantation of kidneys from donors with hepatitis C antibody into recipients pre-transpantation anti-HCV. Hepatitis C virus (HCV) is transmitted by organ transplantation. Consequently, several organ procurement organizations have imposed a moratorium on use of organs from anti-HCV positive donors. Because of the inadequate supply of cadaver kidneys for transplantation, we adopted a policy to transplant kidneys from anti-HCV donors into anti-HCV positive recipients. During the period between March 1990 and December 1992, 24 anti-HCV positive dialysis patients received a kidney from anti-HCV positive donors (group I) and 40 anti-HCV positive patients received a kidney from anti-HCV negative donors (group II). We compared the prevalence of liver disease, anti-HCV, HCV RNA, graft and patient survival between groups.Pre-transplantation 17 of 24 (71%) patients in group I and 31 of 40 (79%) of patients in group II had serum HCV RNA. Post-transplantation follow-up was 26 8 months and 30 10 months in groups I and II, respectively. During follow-up, elevated ALT levels were present in 7 of 24 (29%) and 16 of 40 (40%) of patients in groups I and II, respectively (P> 0.05). Post-transplantation, all patients in both groups retained anti-HCV. The prevalence of HCV RNA post-transplantation was 22 of 23 (96%) patients in group I and 30 of 39 (77%) of patients in group II (P> 0.05). Graft and patient survival in group I (96% and 100%, respectively) were not significantly different from those in group 11(93% and 98%, respectively). The results of this study demonstrate the short-term safety of using kidneys from anti-HCV positive donors in anti-HCV positive recipients.
Therefore, some authors have suggested that kidneys from anti-HCV donors be transplanted into anti-HCV positive recipients [7, 8] .
In Spain, 630 cadaver donors were procured in 1992 [9] .
Nonetheless, more than 6000 patients with chronic renal failure on dialysis are awaiting kidney transplantation [10] . Therefore, in March 1990, the Hospital 12 de Octubre, Madrid, and Hospital Clinic, Barcelona adopted a policy to transplant kidneys from anti-HCV donors into anti-HCV positive recipients, after informed consent from the recipient. Three and one half years after the implementation of this policy, we examined the safety of such transplants. We compared the prevalence of liver disease, anti- 
Clinical Data
Pre-transpiantation. Pre-transplantation records were reviewed (JMM in Madrid and JMC in Barcelona) for age, gender, etiology of chronic renal failure, number of blood transfusions, duration of dialysis, number of previous transplants, history of drug abuse, liver disease or therapy with hepatotoxic drugs, serum alanine aminotransferase (ALT) levels, serological tests for human immunodeficiency virus (HIV), hepatitis B virus (HBsAg, anti-Hbc) and liver histology. Pre-transplantation sera were tested for anti-HCV and for HCV RNA. Liver biopsies were performed before transplantation or in the first month after transplantation.
Post-transplantation. The post-transplantation follow-up included: monitoring of serum ALT levels at monthly intervals; testing of serum for anti-HCV at 3, 6, 9, 12, 18 and 24 months; and testing of serum for HCV RNA at the most recent follow-up. Posttransplantation immunosuppression, incidence of acute rejection, treatment with OKT3, cytomegalovirus infection, date and cause of graft loss and death, and renal function at most recent follow-up were recorded. Thirty-eight patients received steroids (0.5 mg/kg/day) and cyclosporine (10 mg/kg/day), and the others received cyclosporine alone (12 mg/kg/day). In patients with a high titer of lymphocytotoxic antibodies directed against a panel of randomly selected blood donors, primary therapy included antithymocyte globulin (ATG, The Upjohn Company, Kalamazoo, MI, USA) 12 mg/kg/day or muromonab-CD3 (OKT3, Ortho Biotech, Raritan, NJ, USA) 5 mg/kg/day for the first seven days. Acute rejection episodes were treated with intravenous methylprednisolone (1 g) for three days. Corticosteroid resistant rejections were treated with OKT3 (5 mg IV) for 10 to 14 days.
Definitions
Clinical. The presence of liver disease was based on serum alanine aminotransferase (ALT) levels [111. A mild abnormality was defined as increase in ALT, greater than 45 U/L but less than 2.5 times the upper limit of normal. Chronic liver disease was defined as an ALT level greater than 2.5 times the upper limit of normal for more than six months.
Pathological. Diagnosis of minimal changes, acute hepatitis or chronic active hepatitis was based on standard criteria [12, 13] .
Laboratory Tests for HCV Anti-HCV. Donor and recipient sera were tested for anti-HCV using a second generation ELISA (Ortho HCV ELISA 2.0 Test System, Ortho Diagnostic Systems) and a second generation strip immunoblot assay (RIBATM HCV Test System, Chiron Corporation, Emeryville, CA, USA). The second generation ELISA (ELISA2) detected antibody to recombinant HCV antigens (clOO, c200 and c22) from the non-structural and core regions of the HCV genome. The second generation immunoblot assay (RIBA2), detected antibody to antigens (5-1-1, clOO, c33, c22) from the non-structural and core regions of the HCV genome and was used as a supplemental test for anti-HCV [14] . Both tests were carried out according to the manufacturers' instructions.
HCV RNA. All available donor and recipient sera were tested for HCV RNA by polymerase chain reaction (PCR). All donor and recipient samples from each center were tested at a single laboratory at that center.
Methods for PCR at Center I. A nested PCR protocol was used (Ravaggi, PCR Meth App, 1992). Briefly, 3 tL of serum were directly added to 22 tL reverse transcriptase mix (50 mrvi TRIS HC1 pH 8.2, 70 mivi KC1, 10 mrvi MgCl2, 4 mrvi dDT, 40 id of human placental ribonuclease inhibitor, 0.25% nonidet P-40, 50
M of a 5 UTR specific antisense primer (1CH) and 200 LM dNTPs in H20-DEPC). After denaturation for five minutes at 92°C, 4 d of AMV-RT were added, cDNA synthesis was carried out at 42°C for 60 minutes. Amplification was performed following the nested protocol [15] with two set of primers amplifying a fragment located in the 5' non-coding region of the viral genome generating a PCR product of 187 bp. For the demostration of the amplified segments an enzymatic test (DEIA HCV Sorin Biomedica, Salugia, Italy) was used [16] . "P <0.05
Methods for PCR at Center II. RNA was purified from 50 il of serum by the method described by Garson and colleagues [15] .
After reverse transcription of 2 jfl of RNA, a nested PCR was performed using primers from the 5' non-coding region of the HCV genome [17] . The 144 bp amplification products were visualized on polyacrilamide gels by ethidium bromide and ultraviolet light.
At both laboratories, strict precautions were taken to avoid contamination [18] . Positive and negative controls were run in parallel in all experiments.
Statistical analysis
Groups were compared with Student's t-test and the chi-square test (with Yates correction when appropriate). We considered differences between groups significant if the P value was less than 0.05.
Results
Pre-transpiantation Table 1 shows the demographic and clinical characteristics prior to transplantation in recipients of kidneys from donors with anti-HCV (group I) and without anti-HCV (group II). With the exception of the number of blood transfusions (7 8 in group I and 21 39 in group II, P < 0.05) there were no significant differences between the two groups with regard to age, gender, renal disease, duration of dialysis, number of previous transplants, history of drug abuse, prevalence of a positive test for HIV, HbsAg or anti-Hbc. Table 2 compares the prevalence of liver disease prior to transplantation in both groups. Elevated ALT levels were present in 13 of 24 (54%) and 20 of 40 (50%) of patients in groups I and II, respectively. Among patients in group I, four of 13 (31%) patients who had a liver biopsy had histological evidence of liver disease. All four had chronic persistent hepatitis. Among patients in group II, nine of 18 (50%) patients who had a liver biopsy had histological evidence of liver disease. Of these, three had chronic persistent hepatitis, four had chronic active hepatitis and two had hemosiderosis.
All patients in both group I and II were positive by RIBA2.
Seventeen of 24 (71%) patients in group I and 31 of 40 (79%) of patients in group II tested positive for HCV RNA by PCR. Table 2 also compares the outcomes of transplantation in both groups. Post-transplantation follow-up was 26 8 months and 30 10 months in groups I and II, respectively. During follow-up, elevated ALT levels were present in 7 of 24 (29%) and 16 of 40 (40%) of patients in group I and II, respectively (P> 0.05). All patients in group I and II retained anti-HCV by both ELISA2 and RIBA2. Of the patients in whom post-tranplantation sera were available, 22 of 23 (96%) patients in group I and 30 of 39 (77%) of patients in group tested positive for HCV RNA by PCR (P> 0.05). There were no differences in the incidence of acute rejection, OKT3 rescue therapy or cytomegalovirus infection between groups (data not shown). The graft and patient survival in group I (96% and 100%, respectively) were not significantly different from those in group 11(93% and 98%, respectively). The causes of graft loss were obstructive uropathy in the single recipient in group I, and chronic rejection in two recipients in group II. One patient in group II died due to respiratory failure. Serum creatinine levels at the most recent follow-up were similar in groups I and II (1.7 0.4 mg/dl and 1.8 0.5 mg/dl, respectively).
Post-transplantation
Relation of donor and recipients pre-transpiantation HCV RNA to outcomes of transplantation Table 3 shows the results of PCR testing in donors and recipients in group I. Paired donor and recipient (pre-and post-transplantation) sera were available for PCR testing in ten anti-HCV positive donors. Eight donors tested positive for HCV RNA and two tested negative. Kidneys from the eight HCV RNA positive donors were transplanted into fourteen recipients, of whom pre-transpiantation testing for HCV RNA was positive in nine and negative in five. All nine HCV RNA positive recipients of kidneys (100%) tested positive for HCV RNA post-transplantation, and only one (11%) had mild elevation of ALT. Of the five HCV RNA negative recipients, four (80%) tested positive for HCV RNA after transplantation and two (40%) had chronic liver disease after transplantation. Kidneys from the two HCV RNA negative donors were transplanted into two recipients, both of whom tested positive for HCV RNA pre-transplantation. Both recipients tested positive for HCV RNA post-transplantation, and neither had abnormal ALT levels.
Discussion
The prevalence of a positive second generation anti-HCV test among cadaver organ donors is 4.2% and 1.6%, respectively, in the U.S. and Spain, and varies widely among different geographical regions within the countries [6, 9] . Consequently, a moratorium on the use of organs from anti-HCV positive donors would result in a loss of 190 of the 4,520 cadaver donors (up to 380 kidneys) procured in the U.S. in 1992, and 10 of the 630 cadaver donors (up to 20 kidneys) procured in Spain in the same year [9, 19] . The high prevalence of HCV infection among chronic dialysis patients awaiting kidney transplantation, and the existing shortage of cadaver kidneys led us to evaluate the safety of using kidneys from anti-HCV positive donors in anti-HCV positive dialysis patients awaiting transplantation.
Our study shows that the prevalence of post-transplantation liver disease, graft survival and patient survival among anti-HCV positive recipients of kidneys from anti-HCV positive donors was not significantly different from that of anti-HCV positive recipients of kidneys from anti-HCV negative donors. However, the number of patients was small and the duration of follow-up was short. Further, the morbidity and mortality from liver disease is often manifest in the second decade after transplantation [20] [21] [22] .
Hence, the power of the study to detect an adverse effect may have been limited. Nevertheless, such transplants appear to be safe, at least in the short-term. The use of organs from anti-HCV positive donors in anti-HCV positive dialysis patients awaiting transplantation is potentially fraught with problems. First, there are several strains of HCV [23] . Studies in post-transfusion hepatitis C in chimpanzees demonstrated that previous infection with HCV did not protect from reinfection with a different strain or even the same strain of the virus [24] . In fact, repeat exposure did not protect against reappearance of viremia, biochemical or histological evidence of liver disease. Similar data are not available from post-transfusion studies in humans. 
